As of 10:31 on February 26, 2025, the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) rose 1.21% strongly, the constituent stocks InnoCare (09969) rose 8.49%, Gushengtang (02273) rose 6.16%, Pharmacist Bang (09885) rose 5.96%, Genting Xinyao-B (01952), MicroPort Robotics-B (02252) and other stocks followed suit. Hong Kong stock pharmaceutical ETF (159718) rose 2.10%, the latest price was 0.68 yuan, and the intraday turnover has reached 31.1842 million yuan, with a turnover rate of 12.02%, and the market is actively trading.

The CSI Pharmaceutical and Medical Device Innovation Index (931484) rose 0.18%, the constituent stocks Baili Tianheng (688506) rose 4.17%, Yirui Technology (688301) rose 4.05%, Haisco (002653) rose 2.01%, Xingqi Eye Medicine (300573) rose 1.63%, and Jiudian Pharmaceutical (300705) rose 1.46%. Medical Innovation ETF (516820) is long and short, the latest price is 0.34 yuan, and the intraday turnover has reached 17.9002 million yuan, with a turnover rate of 1.01%.

In the long run, as of February 25, 2025, Hong Kong stock pharmaceutical ETFs have risen by 3.41% in the past 1 week. Healthcare Innovation ETF has risen 2.09% over the past 1 week.

In terms of scale, the scale of Hong Kong stock pharmaceutical ETFs has increased by 42.2932 million yuan in the past week, achieving significant growth, and the new scale ranks 2/4 of comparable funds. The latest scale of medical innovation ETF reached 1.762 billion yuan.

In terms of shares, the share of Hong Kong stock pharmaceutical ETF has increased by 54 million shares in the past 1 week, achieving significant growth, and the new share ranks 2/4 of comparable funds. The latest scale of medical innovation ETF reached 1.762 billion yuan.

In terms of capital inflow, Hong Kong stock pharmaceutical ETFs have attracted a total of 36.1885 million yuan in the past five trading days. The latest net inflow of medical innovation ETF was 15.0968 million yuan. In the long run, in the past 5 trading days, a total of 28.2985 million yuan has been "absorbed".

Industry institutions pointed out that the fundamentals of CXO companies in Chinese mainland remain stable, and most leading companies will maintain double-digit net profit growth in 2024, and the share of global orders will continue to increase. The adjustment of the pharmaceutical sector is mainly affected by the sentiment transmission of overseas markets, and some international funds have recently taken a cautious attitude towards the biotechnology industry chain, which has increased the willingness of funds to take profits due to the high valuation of the CXO sector in the early stage.

AI medical catalytic popularity, medical AI assistant DeepSeek has recently been publicly praised by experts from tertiary hospitals, and its ability to diagnose complex cases has aroused the market's expectations for the acceleration of AI medical commercialization. The whole chain supports the gradual implementation of policies and measures for innovative drugs, and the innovative drug sector has ushered in a strong catalyst. AI is expected to empower participants in the medical system such as local offices, hospitals, and pharmaceutical companies to reduce costs and increase efficiency, and it is expected that AI is expected to promote process reengineering in the future in biopharmaceutical, auxiliary diagnosis, and hospital/medical insurance information systems, improve R&D and business efficiency, quality, and reduce costs.

The CSI Hong Kong Stock Connect Medical and Health Composite Index selects 50 securities of listed companies in the medical and health industry with good liquidity and large market capitalization from the Hong Kong Stock Connect as index samples to reflect the overall performance of the securities of medical and health listed companies within the scope of Hong Kong Stock Connect.

According to the data, as of January 28, 2025, the top 10 weighted stocks of the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) are BeiGene (06160), WuXi Biologics (02269), Innovent Biologics (01801), Akeso Biologics (09926), JD Health (06618), CSPC Pharmaceutical Group (01093), Sinobio Biopharm (01177), Sinopharm Group (01099), Alibaba Health (00241), Zai Lab ( 09688), the top 10 weighted stocks accounted for 59.39% of the total.

Hong Kong Pharmaceutical ETF (159718), OTC Connect (Ping An CSI Hong Kong Pharmaceutical ETF Connect A: 019598; Ping An CSI Hong Kong Pharmaceutical ETF Connect C: 019599).

The

CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed companies with good profitability and certain growth and R&D innovation capabilities from the listed companies in the medical and health industry as index samples to reflect the overall performance of the securities of listed pharmaceutical and medical device companies with both profitability and growth.

According to the data, as of January 27, 2025, the top 10 weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) are WuXi AppTec (603259), Hengrui Pharmaceutical (600276), Mindray Medical (300760), Aier Ophthalmology (300015), United Imaging Medical (688271), Kelun Pharmaceutical (002422), Huadong Medicine (000963), Changchun High-tech (000661), and Zhifei Biotechnology (300122). ), Pharmaron (300759), the top 10 weighted stocks accounted for 65.74% of the total.